VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Wednesday, January 7, 2026

Stock Comparison

Boston Scientific Corporation vs Cochlear Limited

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Boston Scientific Corporation

BSX · New York Stock Exchange

Market cap (USD)$141.5B
Gross margin (TTM)65.1%
Operating margin (TTM)17.3%
Net margin (TTM)14.4%
SectorHealthcare
IndustryMedical - Devices
CountryUS
Data as of2026-01-04
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Boston Scientific Corporation's moat claims, evidence, and risks.

View BSX analysis

Cochlear Limited

COH · ASX

Market cap (USD)$17B
Gross margin (TTM)74.5%
Operating margin (TTM)22.7%
Net margin (TTM)16.2%
SectorHealthcare
IndustryMedical - Devices
CountryAU
Data as of2026-01-04
Moat score
81/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Cochlear Limited's moat claims, evidence, and risks.

View COH analysis

Comparison highlights

  • Moat score gap: Cochlear Limited leads (81 / 100 vs 65 / 100 for Boston Scientific Corporation).
  • Segment focus: Boston Scientific Corporation has 5 segments (49.8% in Cardiology); Cochlear Limited has 3 segments (62.4% in Cochlear Implants).
  • Moat breadth: Boston Scientific Corporation has 6 moat types across 3 domains; Cochlear Limited has 8 across 3.

Primary market context

Boston Scientific Corporation

Cardiology

Market

Cardiology devices (interventional cardiology, structural heart, electrophysiology, cardiac rhythm management and remote monitoring)

Geography

Global

Customer

Hospitals/cath labs/EP labs and specialty clinics (cardiologists, electrophysiologists)

Role

Medical device OEM / implantables + procedure devices + service-enabled monitoring

Revenue share

49.8%

Cochlear Limited

Cochlear Implants

Market

Cochlear implant systems (internal implant + external sound processors) for severe-to-profound hearing loss

Geography

Global

Customer

Hospitals/ENT clinics and audiology programs (providers) serving implant candidates/recipients; reimbursed by public/private payers

Role

Medical device OEM / platform owner (implant + processor + fitting software + clinical support)

Revenue share

62.4%

Side-by-side metrics

Boston Scientific Corporation
Cochlear Limited
Ticker / Exchange
BSX - New York Stock Exchange
COH - ASX
Market cap (USD)
$141.5B
$17B
Gross margin (TTM)
65.1%
74.5%
Operating margin (TTM)
17.3%
22.7%
Net margin (TTM)
14.4%
16.2%
Sector
Healthcare
Healthcare
Industry
Medical - Devices
Medical - Devices
HQ country
US
AU
Primary segment
Cardiology
Cochlear Implants
Market structure
Oligopoly
Oligopoly
Market share
n/a
60%-65% (reported)
HHI estimate
n/a
n/a
Pricing power
Moderate
Moderate
Moat score
65 / 100
81 / 100
Moat domains
Demand, Legal, Supply
Demand, Legal, Supply
Last update
2026-01-04
2026-01-04

Moat coverage

Shared moat types

Installed Base Consumables

Boston Scientific Corporation strengths

Procurement InertiaTraining Org Change CostsRegulated Standards PipeReputation ReviewsDistribution Control

Cochlear Limited strengths

Brand TrustCompliance AdvantageCapex Knowhow ScaleIP Choke PointService Field NetworkFormat Lock InData Workflow Lockin

Segment mix

Boston Scientific Corporation segments

Full profile >

Endoscopy

Oligopoly

16%

Urology

Competitive

13.1%

Neuromodulation

Oligopoly

6.6%

Cardiology

Oligopoly

49.8%

Peripheral Interventions

Competitive

14.4%

Cochlear Limited segments

Full profile >

Cochlear Implants

Oligopoly

62.4%

Services

Monopoly

25.9%

Acoustics

Oligopoly

11.7%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Looking for expansion-stage stocks?

Proven models entering the expansion stage with unit economics that work.

View expansion-stage stocks

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.